5-7 февраля в Вене, Австрия, состоится ежегодная конференция DIA Europe 2019. В этом году на конференции ИФАРМА представит первую в России платформу по взаимодействию участников клинических исследований ClinLine.ru. По вопросам организации встреч и переговоров...
In December 2017, IPHARMA received four approvals from the Ministry of health of the Russian Federation to conduct clinical trials. And, according to the results of 2017 (15 approvals), entered the TOP-3 CROs. - BE study of Aberon (abiraterone acetate) ...
The Quality Assurance Forum began its work in June 2017. This Forum assembled quality assurance experts in pharmaceutical industry for the exchange of experience and mutual support. The first meeting of the Forum participants will be held on December 14...
On November 14-15, the 6th International Forum "Clinical trials in Russia" of the Adam Smith Institute was held in Moscow. IPHARMA was one of the major sponsors of the conference. This year, a large pool of interesting speakers including representatives...
On November 13, IPHARMA was authorized by the Ministry of Healthcare of the Russian Federation to conduct the Phase II clinical study of the medicinal product AB5080. Protocol FLU-AV5080-02 “Multicenter, randomized, double-blind, placebo-controlled...
On November 14-16, XXI Russian Oncology Congress passed in Moscow. It is one of the largest international events in the field of oncology, in which more than 5,000 doctors take part annually. Permanent organizers of the congress: N.N. Blokhin Russian...
In early November, IPHARMA received two approvals from the Ministry of Health of the Russian Federation to conduct phase I clinical trials of Ventvil® and Slavinorm® medicinal products. Protocol № HEP-VTL-01 "A double-blind, randomized, placebo...
On November 14-15 the sixth international conference of the Adam Smith Institute "Clinical Research in Russia" will be held . IPHARMA is one of the sponsors of the conference. Under the program the latest regulatory changes, update the ICH GCP...
On October, 30 IPHARMA received the Ministry of Health permission to conduct Phase I trial of Hondrolux®. Protocol № ОА-CLX-01 “Double-blind, randomized, placebo-controlled study to access safety and tolerability of single and following multiple...
Adaptive design is an innovative approach that allows to conduct clinical trials more efficiently (with fewer patients, in shorter terms) or to increase the likelihood of demonstrating the effect of the drug. In studies with adaptation, the possibility of modifying...
The aim of the new addendum is introducing improved and more effective approaches to design development, clinical trials, monitoring of their progress, documentation and reporting, and standards for the maintenance of electronic documentation and mandatory...
On September 18-19 , the annual educational course of the cluster of biomedical research of the Skolkovo Foundation for the Development of Innovative Drugs was held. Representatives of start-ups, pharmaceutical companies and contract research organizations...
On September 14 IPHARMA celebrated the 5th anniversary of the work in the market of clinical trials in the loft on the territory of "Crystal". More than 100 guests, including researchers, partners and customers congratulated IPHARMA. The holiday...
In June 2017, the Eurasian Association for Quality Assurance started business. Experts of quality assurance system of clinical research have united to develop professional area, share experiences and create a community. ChemRar and IPHARMA have become...
On June 14 at 11:00 we will hold a webinar on the "Clinical trials in diabetes: approaches to drug development and methods for effectiveness and safety evaluating". Currently diabetology is one of the most actively developing branches of medical...
On June 2, ASCO Annual Meeting 2017, the main event of the year for specialists in the field of oncology, had started. Annually in Chicago, USA, more than 30,000 medical and pharmaceutical workers gather to discuss modern methods of treatment and innovative...
On May 30, 2017 IPHARMA received Ministry of Health permission to conduct a Phase I clinical trial of CD-008-0045. Protocol No. CD-008-0045 "A double-blind, randomized, placebo-controlled study of the safety, tolerability, and pharmacokinetics of increasing...
On May 22, 2017 IPHARMA received the Ministry of Health permission to conduct clinical trial of Phase I of the drug XC221. Protocol #ARI-XC221-01 "Double-blind randomized placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics...
On May, 24th at 11:00 am, we will hold a webinar on the “Introduction to monitoring: the role of Clinical Research Associate, beginning, responsibilities” . Clinical Research Associate plays the key role in clinical trial. The quality and success...
IPHARMA keeps leading positions among the contract research organizations in local clinical trials ( Research and information bulletin #14 Association of Clinical Trials Organization ACTO April, 6, 2017 ). In 2016 IPHARMA got 10 licences for conducting Phases...
On April 19th at 11:00 a.m. , we will hold the webinar on “GCP for Investigators. Quality assurance system organization in investigator sites” . Organization of quality system is important for the Sponsors and for the investigator sites. Quality...
On June 18-22nd IPHARMA will visit DIA 2017 Annual Meeting in Chicago, USA. IPHARMA will be presenting its business results for a third year running at the conference. We invite you to visit IPHARMA booth #847 to learn more of our company’s achievements...
On April, 12 IPHARMA took a part in XXIV Russian National Congress “Human and drug” . The congress is the partner of Pharma 2020 Programm and aimed to scientific experience and knowledges exchange. Authentic information expansion is the main...
Since March 27th to April 26th Skolkovo Biotechnology and Medical Cluster, Skolkovo Open University and fundamental medicine faculty hold the educational program “Pharma’s Cool 2017” . The program include innovative and technical experience...
On April 15th at 11:00 a.m. , we will hold the webinar on “GCP for Drug developers (Sponsors). Quality Assurance system organization” . Poorly conducted clinical trials mean the lack of them. Quality and safety is the foundation of the pharmaceutical...